CRO

Selvita is a publicly traded, revenue-generating contract research organization (CRO) headquartered in Krakow, Poland, providing end-to-end drug discovery and development services. With a strong focus on oncology and immunology, the company leverages expertise in medicinal chemistry, pharmacology, DMPK, and protein sciences to support clients from target validation through preclinical development and regulatory-ready testing. Operating under GMP and GLP standards, Selvita offers a flexible engagement model for integrated programs or standalone studies, positioning itself as a key scientific partner in the European biotech ecosystem.

Integrated drug discovery and development service platform encompassing medicinal chemistry, in vitro/in vivo biology, DMPK, protein sciences, analytical development, formulation, and GMP/GLP-compliant testing. Expertise in complex cell-based assay development, AI-driven high-content screening analysis, and spatial mass spectrometry imaging.

Competes with large global CROs (e.g., Charles River, LabCorp, Evotec) and numerous specialized regional players. Differentiation is based on integrated service offering from discovery to development, deep therapeutic area expertise in oncology/immunology, and competitive cost structure from its Polish operations.